BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36999776)

  • 1. Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study.
    Zhang XP; Xu S; Gao YX; Zhao ZM; Zhao GD; Hu MG; Tan XL; Lau WY; Liu R
    Int J Surg; 2023 Apr; 109(4):785-793. PubMed ID: 36999776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study.
    Zhang XP; Gao YX; Xu S; Zhao GD; Hu MG; Tan XL; Zhao ZM; Liu R
    Int J Surg; 2022 Oct; 106():106891. PubMed ID: 36165934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?
    Parikh AA; Maiga A; Bentrem D; Squires MH; Kooby DA; Maithel SK; Weber SM; Cho CS; Katz M; Martin RC; Scoggins CR; Sutton J; Ahmad SA; Abbott DE; Carr J; Kim HJ; Yakoub D; Idrees K; Merchant N
    J Am Coll Surg; 2016 Apr; 222(4):448-56. PubMed ID: 26895735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
    Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
    Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma.
    Wen C; Deng X; Ren D; Song X; Chen H; Wang J; Jin J; Cheng D; Xu Z; Zhang J; Xie J; Qi W; Gu J; Peng C; Chen D; Chen S; Shen B; Zhan Q
    Cancer Med; 2020 Oct; 9(20):7626-7636. PubMed ID: 32862515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.
    Ishido K; Kimura N; Wakiya T; Nagase H; Hara Y; Kanda T; Fujita H; Hakamada K
    Ann Surg Oncol; 2022 Feb; 29(2):1281-1293. PubMed ID: 34608555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portal encasement: Significant CT findings to diagnose local recurrence after pancreaticoduodenectomy for pancreatic cancer.
    Noie T; Harihara Y; Akahane M; Kazaoka J; Nagao A; Sato S; Watanabe K; Nara S; Furushima K; Yoshioka R; Yamagata Y; Takeshita E; Okuyama T; Sameshima S; Oya M
    Pancreatology; 2018 Dec; 18(8):1005-1011. PubMed ID: 30241869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study.
    Zou S; Wang X; Chen H; Lin J; Wen C; Zhan Q; Chen H; Lu X; Deng X; Shen B
    BMC Cancer; 2022 Jun; 22(1):649. PubMed ID: 35698045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma.
    Shimagaki T; Sugimachi K; Mano Y; Tomino T; Onishi E; Nakashima Y; Sugiyama M; Yamamoto M; Morita M; Shimokawa M; Yoshizumi T; Toh Y
    PLoS One; 2023; 18(7):e0288033. PubMed ID: 37450554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery.
    Hsu CP; Lee LY; Hsu JT; Hsu YP; Wu YT; Wang SY; Yeh CN; Chen TC; Hwang TL
    In Vivo; 2018; 32(6):1533-1540. PubMed ID: 30348713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study.
    Uemura K; Murakami Y; Satoi S; Sho M; Motoi F; Kawai M; Matsumoto I; Honda G; Kurata M; Yanagimoto H; Nishiwada S; Fukumoto T; Unno M; Yamaue H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1238-46. PubMed ID: 26014151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center.
    Zhang XP; Xu S; Zhao ZM; Liu Q; Zhao GD; Hu MG; Tan XL; Liu R
    Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):140-146. PubMed ID: 36171169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resection margin status at the portomesenteric axis may not determine oncologic outcome after pancreaticoduodenectomy for lymph node-positive pancreatic ductal adenocarcinoma.
    Katou S; Wenning AS; Aeschbacher P; Morgul H; Becker F; Pascher A; Gloor B; Strücker B; Andreou A
    Surgery; 2023 Jul; 174(1):91-99. PubMed ID: 37121858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel combined carbohydrate antigen 19-9 and lymphocyte-to-monocyte ratio score can predict early recurrence of resectable pancreatic ductal adenocarcinoma.
    Yugawa K; Maeda T; Nagata S; Sakai A; Taketani K; Yamaguchi S; Konishi K; Hashimoto K
    Surg Today; 2023 Oct; 53(10):1199-1208. PubMed ID: 36943449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection.
    Xu J; Lyu S; Zhao Y; Zhang X; Liu Z; Zhao X; He Q
    Technol Cancer Res Treat; 2022; 21():15330338221078438. PubMed ID: 35138217
    [No Abstract]   [Full Text] [Related]  

  • 18. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for early recurrence after pancreaticoduodenectomy in patients with resectable pancreatic head cancer: A multicenter retrospective study.
    Ono S; Adachi T; Ohtsuka T; Kimura R; Nishihara K; Watanabe Y; Nagano H; Tokumitsu Y; Nanashima A; Imamura N; Baba H; Chikamoto A; Inomata M; Hirashita T; Furukawa M; Idichi T; Shinchi H; Maruyama Y; Nakamura M; Eguchi S
    Surgery; 2022 Dec; 172(6):1782-1790. PubMed ID: 36123175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S
    Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.